NEXTURNBIOSCIENCE Co., LTD
089140 | KO
Overview
Corporate Details
- ISIN(s):
- KR7089140008
- LEI:
- Country:
- South Korea
- Address:
- 경기도 용인시 기흥구 기흥단지로121번길 35 (고매동), 용인시
- Website:
- http://www.nexturn.co.kr
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-26 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
|
Korean | 107.5 KB | ||
| 2025-08-25 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
|
Korean | 69.6 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.5 MB | ||
| 2025-08-07 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.1 KB | ||
| 2025-08-07 00:00 |
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
|
Korean | 9.5 KB | ||
| 2025-08-01 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 86.1 KB | ||
| 2025-07-30 00:00 |
Share Issue/Capital Change
전환청구권행사
|
Korean | 9.1 KB | ||
| 2025-07-28 00:00 |
Share Issue/Capital Change
전환가액의조정
|
Korean | 10.7 KB | ||
| 2025-07-16 00:00 |
Share Issue/Capital Change
[기재정정]주요사항보고서(자기전환사채매도결정)
|
Korean | 62.7 KB | ||
| 2025-07-16 00:00 |
M&A Activity
주요사항보고서(회사합병결정)
|
Korean | 95.5 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 6.0 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.1 KB | ||
| 2025-07-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.7 KB | ||
| 2025-07-03 00:00 |
M&A Activity
합병등종료보고서(합병)
|
Korean | 21.8 KB |
Automate Your Workflow. Get a real-time feed of all NEXTURNBIOSCIENCE Co., LTD filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for NEXTURNBIOSCIENCE Co., LTD
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for NEXTURNBIOSCIENCE Co., LTD via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Maps immune genetics for blood cancer diagnostics and drug discovery partnerships.
United States of America
ADPT
United States of America
ADPT
Invents and licenses foundational IP for the media and semiconductor industries.
United States of America
ADEA
United States of America
ADEA
Acquires and develops biotech for autoimmunity, cancer detection, and neuro diagnostics.
United States of America
ADTX
United States of America
ADTX
Develops microfluidic biochips for rapid, affordable liquid biopsy in precision oncology.
United States of America
ADVB
United States of America
ADVB
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
United States of America
AIM
Develops AI-powered 'SmellTech' diagnostics and immune therapies for point-of-care testing.
United States of America
AIMD
United States of America
AIMD
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
United States of America
AKRO
Develops AI for drug discovery and diagnostics targeting age-related diseases.
Germany
NMI
Germany
NMI
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
United States of America
TCRT
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
United States of America
ALGS